[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100468993":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":11,"centralContacts":43,"locations":50,"responsibleParty":66,"collaborators":11,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":11,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":11,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"UBT","EXPERIMENTAL",null,[13],"Diagnostic Test: UBT",{"label":15,"type":10,"description":11,"interventionNames":16},"HpSA",[17],"Diagnostic Test: HPSA",{"label":19,"type":10,"description":11,"interventionNames":20},"Standard method",[21],"Diagnostic Test: UBT and HPSA",{"label":23,"type":10,"description":11,"interventionNames":24},"Two-stage screening method",[25],"Diagnostic Test: Serology (two stage)",[27,31,35,39],{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":11},"DIAGNOSTIC_TEST","H. pylori diagnostic test: C13 urea breath test",[9],{"type":28,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"HPSA","H. pylori diagnostic test: H. pylori stool antigen test",[15],{"type":28,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"UBT and HPSA","H. pylori diagnostic tests: H. pylori serology test, C13 urea breath test",[19],{"type":28,"name":40,"description":41,"armGroupLabels":42,"otherNames":11},"Serology (two stage)","H. pylori diagnostic test: If H. pylori serology is positive, confirmation UBT will be done.",[23],[44],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Jyh-Ming Liou, MD,PhD","CONTACT","886-2-23123456","63541","jyhmingliou@gmail.com",[51],{"facility":5,"status":52,"city":53,"state":11,"zip":11,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Taipei","Taiwan","TW",{"type":57,"coordinates":58},"Point",[59,60],121.52639,25.05306,{"lat":60,"lon":59},[63],{"name":64,"role":46,"phone":65,"phoneExt":11,"email":49},"Jyh-Ming Liou Liou, MD, PhD","886-2-23123456 Ext. 63541",{"type":67,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100468993","screening-strategy-for-gastric-cancer-prevention-100468993",false,"NCT05387005","Screening Strategy for Gastric Cancer Prevention","Identification of the Optimal Screening Strategy for Gastric Cancer Prevention","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Never screened and treated for H. pylori infection\n\nExclusion Criteria:\n\n* Ever undergone gastrectomy\n* Patients with gastric cancer\n* Have been screened or tested for H. pylori infection\n* Ever received H. pylori eradication therapy\n* Have taken proton pump inhibitor within two weeks\n* Have taken antibiotics within two weeks",true,"ALL","20 Years",{"count":79,"type":80},4403,"ESTIMATED","INTERVENTIONAL",[83],"NA","There are still some unsolved questions regarding population-based screening program for H. pylori infection to prevent gastric cancer, such as how to perform the optimal screening strategies. A prospective, randomized trial will be conducted to compare the acceptability, compliance (\u002Fadherence), and accuracy of diagnostic tests in a population-based H. pylori screening and gastric cancer prevention program.\n\nInitially, we planned to recruit 10,000 adults aged ≥20 years who had not previously undergone H. pylori screening or treatment. Eligible participants were to be randomly allocated in a 1:1:1:1 ratio to one of four groups, each receiving a different combination of diagnostic tests. However, a preliminary analysis led to a recalculation of the required sample size. Following the approval of an Institutional Review Board (IRB) amendment, enrollment was discontinued for Group B (HpSA method) and Group D (Two-stage screening method). The final number of participants enrolled in Group B and Group D was 852 and 851, respectively. Groups A (UBT method) and Group C (standard method) will continue to enroll participants through an additional 1:1 randomization until each group reaches a total of 1,350 participants.",[86],"H. Pylori Infection",[88,89],"H. pylori","screening","2025-08-13",{"date":92,"type":93},"2025-08-17","ACTUAL",{"date":95,"type":93},"2022-07-19",{"date":97,"type":80},"2029-04-30",{"name":5,"class":6},1]